Blog

Andrea Apolo: Very proud of Saad Atiq for presenting data at ASCO25

Andrea Apolo/X

Jun 3, 2025, 12:27

Andrea Apolo: Very proud of Saad Atiq for presenting data at ASCO25

Andrea Apolo, Director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic at the National Cancer Institute, shared a post on X:

“Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the Bladder showing 1/3 of patients with TMB-High.”

Andrea Apolo highlighted new findings presented by Saad Atiq on histology-agnostic biomarkers in pure squamous cell carcinomas of the bladder. The data revealed that one-third of these patients exhibited TMB-High, indicating potential implications for targeted therapies.

More posts featuring Andrea Apolo.

Agnostic Biomarkers Andrea Apolo ASCO25 bladder cancer cancer fight against cancer Genitourinary tumors Global fight against cancer National Cancer Institute NCI OncoDaily Oncology Saad Atiq squamous cell carcinomas TMB-High

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer